Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Double-blind, Double-dummy, Placebo- and Active-controlled, 6-way Cross-over Study to Evaluate the Abuse Potential of Single, Oral Doses of ACT-541468 in Healthy Recreational Drug Users

Trial Profile

Randomized, Double-blind, Double-dummy, Placebo- and Active-controlled, 6-way Cross-over Study to Evaluate the Abuse Potential of Single, Oral Doses of ACT-541468 in Healthy Recreational Drug Users

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 30 Mar 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Daridorexant (Primary) ; Suvorexant; Zolpidem
  • Indications Insomnia
  • Focus Pharmacodynamics
  • Sponsors Idorsia Pharmaceuticals
  • Most Recent Events

    • 14 Mar 2022 Primary endpoint (Maximum effect (Emax) of the Drug Liking VAS (at this moment) over 24 h post-dose during each treatment period) has been met according to the results published in the Sleep
    • 14 Mar 2022 Results published in the Sleep
    • 15 Sep 2020 Results presented at the 33rd Annual Congress of the European College of Neuropsychopharmacology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top